Cancer, Chronic Pain
Conditions
Keywords
cancer treatment protocols, chronic cancer pain, cognitive function, quality of life, anxiety, depression
Brief summary
The aim of this study is to investigate the predictive dimension of cognitive-emotional status of cancer patients on the chronic pain development 6 months after different cancer treatment protocol (surgery, chemotherapy, radiotherapy, hormone therapy, targeted therapy ...).
Detailed description
This is an observational, longitudinal and multicenter study assessing in cancer patients the link between the cognitive-emotional status and the development of chronic pain. Cognition, anxiety, depression, quality of life, social vulnerability, cancer perception, pain and analgesic consumption are assessed.
Interventions
OTHERchronic pain
Sponsors
University Hospital, Clermont-Ferrand
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Cancer patient with one or more programmed cancer treatment protocols (chemotherapy, surgery, hormone therapy, radiation therapy, targeted therapy, ...) * Acceptance to sign the non-opposition form
Exclusion criteria
* History of cancer and cancer treatment protocols (chemotherapy, surgery, hormone therapy, radiation therapy, targeted therapy, ...) * History and/or presence of primary brain tumors (glioblastoma, meningioma, neurofibroma ...) * History of neurological disorders (Parkinson's disease, Alzheimer's disease, dementia, epilepsy, moderate to severe head injury, ...) * History of psychiatric disorders (schizophrenia, bipolar disorder, ...) * Medical and surgical history incompatible with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of average pain intensity by a numerical rating scale | 7 days before the visit | Measure of average pain intensity by a numerical rating scale assessed 7 days before the 6 months visit after inclusion of patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of analgesic consumption | at day 1 | Analgesic consumption is evaluated during all period of the study (name of the specialty, dose, indication, form, administration route, starting date, end date), |
| Cognitive assessment by Trail Making Test A and B (TMT) | at baseline | — |
| Rey Auditory-Verbal Learning Test (RAVLT) and FACT-COG | at baseline | — |
| Quality of life assessment | at baseline, 6 months, 12 months and 24 months, | Quality of life assessment by: \- The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), at baseline, 6 months, 12 months and 24 months. This questionnaire assesses the quality of life of cancer patients. It is divided in 9 subscales consisting of several items: 5 subscales measuring functional status (physical, role, social, emotional, cognitive), three subscales measuring symptoms (fatigue, pain, nausea and vomiting) and a global subscale of quality of life and health. Finally, six items/isolated symptoms, covering cancer symptoms and frequent side effects of cancer therapies (e.g. loss of appetite) are also included in the EORTC QLQ-C30. The EORTC QLQ-C30 Score ranges from 0 to 126 |
| Pain assessment by numerical rating scale and DN4 | at baseline | — |
| Anxiety and Depression assessment by HAD scale | at baseline, 6 months, 12 months and 24 months | — |
| Illness perception assessment | at baseline, 6 months, 12 months and 24 months | Global score ranges from 0 to 200 |
| Coping strategies assessment by Coping strategies questionnaire (CSQ) | 2 days after each cancer treatment protocol. | — |
| Social vulnerability assessment by EPICES questionnaire | at baseline, 6 months, 12 months and 24 months | — |
Countries
France
Outcome results
None listed